









Markets
/
Stocks
/
nasdaq-eton
/

Eton Pharmaceuticals Inc

ETON

14.760USD

+0.410+2.86%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

395.83MMarket Cap

LossP/E TTM



Eton Pharmaceuticals Inc

14.760

+0.410+2.86%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Eton Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Eton Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eton Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

67 / 159

Overall Ranking

182 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Eton Pharmaceuticals Inc Highlights

StrengthsRisks

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 83.57% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 39.01M.

Fairly Valued

The company’s latest PE is -59.29, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.82M shares, decreasing 0.00% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 6.44K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.64.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

30.000

Target Price

+109.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Eton Pharmaceuticals Inc is 7.71, ranking 99 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 22.46M, representing a year-over-year increase of 117.54%, while its net profit experienced a year-over-year increase of 407.34%.

Score

Industry at a Glance

Previous score

7.71

Change



Financials

8.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Eton Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Eton Pharmaceuticals Inc is 7.37, ranking 76 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -59.29, which is -274.58% below the recent high of 103.51 and -1089.96% above the recent low of -705.51.

Score

Industry at a Glance

Previous score

7.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Eton Pharmaceuticals Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 29.00, with a high of 35.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

30.000

Target Price

+109.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Eton Pharmaceuticals Inc

ETON

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Eton Pharmaceuticals Inc is 6.97, ranking 92 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 16.10 and the support level at 13.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.65

Change

0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.027

Sell

RSI(14)

41.263

Neutral

STOCH(KDJ)(9,3,3)

28.121

Neutral

ATR(14)

0.587

Low Volatility

CCI(14)

-117.901

Sell

Williams %R

66.385

Sell

TRIX(12,20)

-0.368

Sell

StochRSI(14)

56.144

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

14.884

Sell

MA10

14.959

Sell

MA20

15.163

Sell

MA50

15.902

Sell

MA100

17.279

Sell

MA200

16.789

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Eton Pharmaceuticals Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 61.06%, representing a quarter-over-quarter decrease of 0.01%. The largest institutional shareholder is The Vanguard, holding a total of 1.35M shares, representing 5.03% of shares outstanding, with 22.50% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Opaleye Management Inc.

2.86M

EcoR1 Capital, LLC

2.03M

BlackRock Institutional Trust Company, N.A.

1.56M

+11.48%

The Vanguard Group, Inc.

Star Investors

1.34M

+2.43%

Nantahala Capital Management, LLC

1.18M

Brynjelsen (Sean E)

858.21K

-0.78%

Geode Capital Management, L.L.C.

574.03K

-3.18%

RBC Dominion Securities, Inc.

478.80K

+273500.00%

Westside Investment Management, LLC

472.54K

-0.05%

Morgan Stanley & Co. LLC

461.32K

+47.87%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Eton Pharmaceuticals Inc is 5.75, ranking 63 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Eton Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.